Aptus Capital Advisors LLC Invests $4.48 Million in LeMaitre Vascular, Inc. $LMAT

Key Points

• Aptus Capital Advisors LLC acquired 53,428 shares of LeMaitre Vascular, valued at approximately $4.48 million, representing about 0.24% of the company as of the latest SEC filing.
• CEO George W. Lemaitre sold 100,000 shares for $9.35 million, marking a 5.47% decrease in his ownership position.
• LeMaitre Vascular recently reported earnings of $0.60 per share, exceeding analysts' expectations, and announced a quarterly dividend of $0.20 per share to be paid on September 4th.

Aptus Capital Advisors LLC purchased a new position in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 53,428 shares of the medical instruments supplier's stock, valued at approximately $4,483,000. Aptus Capital Advisors LLC owned approximately 0.24% of LeMaitre Vascular as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in LMAT. Opal Wealth Advisors LLC purchased a new stake in LeMaitre Vascular in the 1st quarter worth $26,000. NBC Securities Inc. purchased a new stake in LeMaitre Vascular in the 1st quarter worth $36,000. US Bancorp DE increased its holdings in LeMaitre Vascular by 36.0% in the 1st quarter. US Bancorp DE now owns 1,390 shares of the medical instruments supplier's stock worth $117,000 after acquiring an additional 368 shares in the last quarter. Canada Pension Plan Investment Board increased its holdings in LeMaitre Vascular by 112.5% in the 4th quarter. Canada Pension Plan Investment Board now owns 1,700 shares of the medical instruments supplier's stock worth $157,000 after acquiring an additional 900 shares in the last quarter. Finally, Summit Investment Advisors Inc. increased its holdings in LeMaitre Vascular by 8.2% in the 4th quarter. Summit Investment Advisors Inc. now owns 2,122 shares of the medical instruments supplier's stock worth $196,000 after acquiring an additional 160 shares in the last quarter. Hedge funds and other institutional investors own 84.64% of the company's stock.

Insiders Place Their Bets

In other LeMaitre Vascular news, Director John A. Roush sold 6,561 shares of LeMaitre Vascular stock in a transaction on Monday, August 11th. The stock was sold at an average price of $92.55, for a total value of $607,220.55. Following the sale, the director owned 2,916 shares in the company, valued at $269,875.80. The trade was a 69.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director David B. Roberts sold 10,815 shares of the company's stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $92.39, for a total transaction of $999,197.85. Following the completion of the transaction, the director directly owned 17,976 shares in the company, valued at $1,660,802.64. The trade was a 37.56% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 120,815 shares of company stock worth $11,280,206 over the last ninety days. Company insiders own 9.50% of the company's stock.

LeMaitre Vascular Trading Down 0.8%

Shares of LMAT stock traded down $0.83 on Monday, hitting $99.50. 50,724 shares of the stock traded hands, compared to its average volume of 189,419. The firm's 50-day moving average price is $85.98 and its two-hundred day moving average price is $86.31. The company has a debt-to-equity ratio of 0.46, a quick ratio of 11.74 and a current ratio of 13.96. The stock has a market capitalization of $2.25 billion, a PE ratio of 47.91, a PEG ratio of 2.58 and a beta of 0.79. LeMaitre Vascular, Inc. has a twelve month low of $71.42 and a twelve month high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.03. The firm had revenue of $63.15 million for the quarter, compared to analysts' expectations of $62.48 million. LeMaitre Vascular had a net margin of 20.08% and a return on equity of 13.67%. The company's revenue was up 15.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS. LeMaitre Vascular has set its Q3 2025 guidance at 0.540-0.590 EPS. FY 2025 guidance at 2.230-2.370 EPS. As a group, analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 4th. Shareholders of record on Thursday, August 21st will be given a $0.20 dividend. The ex-dividend date is Thursday, August 21st. This represents a $0.80 dividend on an annualized basis and a yield of 0.8%. LeMaitre Vascular's payout ratio is currently 38.83%.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. Barrington Research raised LeMaitre Vascular from a "market perform" rating to an "outperform" rating and set a $95.00 price target on the stock in a research note on Wednesday, August 6th. Cantor Fitzgerald upped their target price on shares of LeMaitre Vascular from $92.00 to $95.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Two investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $97.60.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.